ESPOIR2
What it found
No result yet.
What was tested
Treatment tested
- MRI
What it measured
Main measures
estimate the number of lesions detected with the 3D FGAPSIR sequence and not detected with the 3D PSIR sequence.
1 DAY
MRI lesions
Who could take part
MS (type not specified) · 18 and over
Inclusion Criteria: * Patient over 18 years old * To benefit from a medullary exploration planned by 3T MRI as part of a first evaluation or a reassessment of inflammatory involvement of the nevrax * Express consent to participate in the study * Affiliate or beneficiary of a social security scheme Exclusion Criteria: * Patient benefiting from a legal protection measure * Pregnant, parturient or breastfeeding woman * Absolute or relative contraindication to MRI
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
* verification of inclusion and non-inclusion criteria * information and collection of consent * standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), 3D STIR and 3D PSIR sequence. * 3D FGAPSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes)
Loading reviews and guidelines…
History
Started
Oct 2023
Main results due
Oct 2026
Finished
Oct 2026
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error